Diagnostik und Therapie der akuten myeloischen Leukämie

Literatur

• 1 Bennett J M, Catovsky D, Daniel M T. et al . Proposals for the classification of the acute leukaemias. French- American-British (FAB) co-operative group.  Br J Haematol. 1976;  33 451-458
• 2 Jaffe E S, Harris N L, Stein H, Vardiman J W. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press 2001
• 3 Haferlach T, Schoch C, Schnittger S, Kern W, Loffler H, Hiddemann W. Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study on 124 patients.  Br J Haematol. 2002;  118 426-431
• 4 Haferlach T, Schoch C. WHO classification of acute myeloid leukaemia (AML) and the myelodysplastic syndrome (MDS).  Dtsch Med Wochenschr. 2002;  127 447-450
• 5 Schoch C, Haferlach T, Haase D. et al . Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.  Br J Haematol. 2001;  112 118-126
• 6 Grimwade D, Walker H, Oliver F. et al . The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties.  Blood. 1998;  92 2322-2333
• 7 Schoch C, Kern W, Krawitz P. et al . Dependence of age-specific incidence of acute myeloid leukemia on karyotype.  Blood. 2001;  98 3500
• 8 Lengfelder E, Reichert A, Schoch C. et al. German AML Cooperative Group . Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia.  Leukemia. 2000;  14 1362-1370
• 9 Ostermann H, Derigs H G, Heussel G. et al . Sepsis in neutropenia. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association for Hematology and Oncology.  Dtsch Med Wochenschr. 1999;  124 S14-S17 (Suppl 1)
• 10 Buchner T, Hiddemann W, Wormann B. et al . Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group.  Blood. 1999;  93 4116-4124
• 11 Kern W, Haferlach T, Schoch C. et al . Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group 1992 Trial.  Blood. (in press); 
• 12 Hiddemann W, Kern W, Schoch C. et al . Management of acute myeloid leukemia in elderly patients.  J Clin Oncol. 1999;  17 3569-3576
• 13 Mayer R J, Davis R B, Schiffer C A. et al. Cancer and Leukemia Group B . Intensive postremission chemotherapy in adults with acute myeloid leukemia.  N Engl J Med. 1994;  331 896-903
• 14 Buchner T, Urbanitz D, Hiddemann W. et al . Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.  J Clin Oncol. 1985;  3 1583-1589
• 15 Cassileth P A, Harrington D P, Appelbaum F R. et al . Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission (see comments).  N Engl J Med. 1998;  339 1649-1656
• 16 Kern W, Schoch C, Fonatsch C. et al . Therapie der akuten myeloischen Leukämie bei Patienten im höheren Lebensalter.  Dtsch Med Wochenschr. 1999;  124 1005-1014
• 17 Leith C P, Kopecky K J, Godwin J. et al. A Southwest Oncology Group study . Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy.  Blood. 1997;  89 3323-3329